Which semaglutide option is right for you?

Injection or tablet: the practical trade-offs that actually matter

Most people arrive at this question holding a misconception worth addressing calmly: that the injection must work better simply because it came first. The evidence does not support that. The Wegovy tablet, studied in the OASIS 4 phase-3 trial over 64 weeks, produced an average weight loss of roughly 13.6% regardless of adherence, and around 17% among participants who stayed fully adherent throughout. The injection at 2.4 mg has shown approximately 15% average reduction in the STEP 1 trial, published in the New England Journal of Medicine. The gap narrows considerably when you factor in the 7.2 mg injection dose, which trials reported at around 20.7% average loss over 72 weeks. No two of these figures came from the same study design, so direct comparisons are imprecise, what matters is which option fits your life well enough for you to stay on it.

For the injection, Wegovy is supplied as a pre-filled pen, given once a week into the abdomen, thigh or upper arm, rotating sites. It requires refrigeration. For the tablet, no refrigeration is needed, it is taken first thing in the morning on an empty stomach with a small amount of plain water, and you wait at least 30 minutes before food, drink or other oral medicines. That morning routine either suits you or it does not, and that is a fair thing to weigh. Travelling with a tablet is simpler than managing cold-chain storage for a pen.

Which semaglutide option the licensing and the evidence actually cover

Wegovy injection is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes are common examples. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The NHS medicines page for semaglutide covers the full side-effect and contraindication profile for the injection. Wegovy tablets carry the same general BMI eligibility frame.

Ozempic sits in a separate category entirely. It contains semaglutide at 0.5 mg, 1 mg and 2 mg doses, and the MHRA has authorised it for blood-sugar control in type 2 diabetes, not for weight management. Prescribing it off-label for weight loss is not something a responsible prescriber does when licensed weight-management alternatives exist. If someone is offering it to you for weight loss through an online channel, that is worth treating with scepticism. The NICE appraisal of Wegovy (TA875) sets out what the evidence looks like for licensed semaglutide in weight management specifically.

Rybelsus is another oral semaglutide, but at 3 mg, 7 mg and 14 mg strengths for type 2 diabetes, not the weight-loss tablet. These are entirely different products. If you want to understand how the semaglutide options for weight loss differ from diabetes-licensed products and where each sits within the licensed landscape, that page sets out the distinctions clearly. Wegovy tablets dose at 1.5 mg, 4 mg, 9 mg and 25 mg; the Rybelsus strengths do not form part of that ladder.

How the dose schedules shape your first few months

Both licensed weight-management forms of semaglutide start low and titrate upward. The injection begins at 0.25 mg weekly, stepping roughly every four weeks through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, with 7.2 mg now available as a higher maintenance option for adults with a BMI of 30 or above, dispensed as a dedicated single-dose pen approved by the MHRA in April 2026. The tablet begins at 1.5 mg daily, moving through 4 mg and 9 mg to the 25 mg maintenance dose, with at least a month at each level.

The slow start is deliberate. Gastrointestinal effects (nausea, loose stools, indigestion) are the most common complaints with semaglutide, and they tend to be at their most noticeable after starting or stepping up a dose. Gradual titration reduces how disruptive they are. Most people find these effects settle within a couple of weeks of each new level. Staying well hydrated and eating smaller, lower-fat meals helps. You can read more about the broader clinical profile of semaglutide and how it sits alongside lifestyle changes.

On the question of cost: Wegovy options differ in price, and the private market has moved considerably since Eli Lilly's list-price change in September 2025 reshaped what providers charge across the board. For a grounded look at what private semaglutide treatment typically costs, the Wegovy price guide lays out the market context honestly. Pricing for a prescription medicine should be the last thing you evaluate, not the first, clinical fit, genuine supply chain and proper ongoing oversight matter more.

Making the decision: what a prescriber will want to know

A prescriber reviewing your case will look at your BMI, your weight-related health conditions, your medication history (oral contraceptives with tirzepatide have a specific interaction note; for semaglutide the evidence is different), whether you have a history of pancreatitis or certain thyroid conditions, and how your daily routine maps onto each formulation's demands. They will also ask whether you are pregnant, trying to conceive or breastfeeding, semaglutide is not recommended in any of those situations, and a wash-out period before trying to conceive is advised.

If you are already taking another weight-management medicine and considering switching, or if you have been on the injection and want to explore whether the tablet suits you better, those are exactly the conversations to have with a prescriber rather than making the switch independently. You can explore the full range of weight-loss treatment options and check whether you are likely to be eligible before your consultation. If your insurer has raised the topic, it is also worth reviewing what AXA covers for Wegovy before you consult, so you go in with a clear picture of your funding position. Our clinical team reviews every consultation personally (not a screening algorithm) and the same-day review means you are not waiting days for an answer. If you have questions before starting, the FAQs cover the most common ones, or you can get in touch directly.

Speak to our prescribers when you are ready, the consultation is free, there is no subscription, and every repeat order is clinically reviewed before dispatch. If you are partway through the titration schedule and want to understand what the semaglutide 1 mg stage involves clinically, or what changes when you move to the semaglutide 2 mg stage, those pages cover each step in detail.